Kymera Therapeutics, Inc.

Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule therapeutics using targeted protein degradation. The company's technology engages cellular recycling machinery to selectively eliminate disease-causing proteins, particularly historically undrugged transcription factors and scaffolding proteins. Its pipeline centers on immunology programs, including KT-621 targeting STAT6 for inflammatory conditions such as atopic dermatitis and asthma, and KT-579 targeting IRF5 for autoimmune disorders. Kymera also advances partnered programs, including an IRAK4 degrader with Sanofi and cyclin-dependent kinase 2 molecular glue degraders with Gilead Sciences, alongside early-stage oncology research. The company targets patients suffering from immune-inflammatory diseases and cancers.

The company operates without internal manufacturing facilities, outsourcing the production of its drug substances and clinical products to third-party contract manufacturers on a purchase order basis. Kymera’s research and development initiatives address patient populations across the United States, Europe, and Japan. The provided text discusses collaborative agreements and clinical development across these regions, though it does not specify a headquarters location.

Summary of the business section of Kymera Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 238 full-time employees.”